Back to Search
Start Over
Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13.
- Source :
-
PloS one [PLoS One] 2017 Jan 09; Vol. 12 (1), pp. e0169675. Date of Electronic Publication: 2017 Jan 09 (Print Publication: 2017). - Publication Year :
- 2017
-
Abstract
- We examined the connection between matrix metalloproteinase (MMP) expression/activity and pterygium fibroblast migration, and how these were affected by bevacizumab and/or cyclosporine A (CsA). Fibroblasts were obtained from 20 pterygia and 6 normal conjunctival specimens. Expression levels of MMP-3 and MMP-13 were examined after bevacizumab administration. Immunofluorescence staining was used to examine expression of both MMPs in fibroblasts migrating out from explanted pterygium tissues. Rates of cell migration from explant-cultured pterygia tissues and scratch-wounded confluent pterygium fibroblasts were examined in the presence of MMP-3 or MMP-13 inhibitors, as well as bevacizumab and/or CsA. A scratch wound healing migration assay was performed to determine the effects of bevacizumab and/or CsA. Protein expression of both MMPs in pterygium tissues and in cells migrating from organ-cultured pterygium tissues was greater than that observed in normal cells. Inhibition of the activities of both MMPs decreased their expression levels; these were also significantly reduced in bevacizumab-injected pterygium tissues. Bevacizumab significantly reduced the expression of both MMPs and cell migration. Pretreatment with CsA prior to bevacizumab exposure markedly inhibited cell migration and the expression of both MMPs. CsA enhanced the inhibitory effects of bevacizumab on pterygium fibroblast migration in vitro, possibly by inhibiting expression of both MMPs. These findings suggest that combined CsA and bevacizumab treatment may provide a potential therapeutic strategy for reducing the rate of pterygium recurrence.<br />Competing Interests: The authors have declared that no competing interests exits.
- Subjects :
- Cell Movement drug effects
Cell Movement genetics
Down-Regulation
Female
Gene Expression Regulation drug effects
Humans
Immunohistochemistry
Male
Matrix Metalloproteinase 13 genetics
Matrix Metalloproteinase 3 genetics
Bevacizumab pharmacology
Cyclosporine pharmacology
Fibroblasts drug effects
Fibroblasts metabolism
Matrix Metalloproteinase 13 metabolism
Matrix Metalloproteinase 3 metabolism
Pterygium metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 12
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 28068383
- Full Text :
- https://doi.org/10.1371/journal.pone.0169675